Abstract Number: 2966 • 2017 ACR/ARHP Annual Meeting
Impact of Tofacitinib Treatment Compared with Placebo or Methotrexate on Cardiovascular Risk Scores in Six Phase 3 Randomized Controlled Trials
Background/Purpose: Patients (pts) with RA are at increased risk of myocardial infarction and stroke not fully explained by usual cardiovascular (CV) risk factors. Tofacitinib is…Abstract Number: 2967 • 2017 ACR/ARHP Annual Meeting
Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort
Background/Purpose: While, a Treat-to-Target strategy (T2T), treating patients with rheumatoid arthritis (RA) towards a certain target (eg. clinical remission; T2T-REM), is highly recommended, several patients…Abstract Number: 2968 • 2017 ACR/ARHP Annual Meeting
Less Fatigue in Psoriatic Arthritis after High Intensity Interval Training. a Randomized Controlled Trial
Background/Purpose: Patients with psoriatic arthritis (PsA) have a high disease burden with increased pain and more fatigue than the general population. Physical exercise is recommended…Abstract Number: 2969 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In patients with active psoriatic arthritis (PsA) who had an inadequate response…Abstract Number: 2970 • 2017 ACR/ARHP Annual Meeting
Inhibition of Radiographic Progression in Psoriatic Arthritis By Adalimumab Independent of the Control of Clinical Disease Activity
Background/Purpose : Patients (pts) with psoriatic arthritis (PsA) may experience structural damage and irreversible functional impairment if not treated appropriately. Treatment with TNF inhibitors in…Abstract Number: 2971 • 2017 ACR/ARHP Annual Meeting
What Do Reduced 28 Joint Counts Miss in Patients with Psoriatic Arthritis?
Background/Purpose: Clinical joint assessment by the rheumatologist is a key examination of patients with psoriatic arthritis (PSA). A clinically swollen joint is predicting subsequent joint…Abstract Number: 2972 • 2017 ACR/ARHP Annual Meeting
Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study
Background/Purpose: There is conflicting data on the risk of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Ankylosing Spondylitis (AS). This study attempts…Abstract Number: 2973 • 2017 ACR/ARHP Annual Meeting
Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…Abstract Number: 2974 • 2017 ACR/ARHP Annual Meeting
B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Background/Purpose: SLE is characterized by the dysregulation of humoral immunity including high levels of autoreactive IgG VH4.34 antibodies recognized by the rat anti-human idiotypic antibody…Abstract Number: 2975 • 2017 ACR/ARHP Annual Meeting
Using Immune and Metabolic Phenotyping to Understand the Immunopathogenesis of Juvenile-Onset SLE and Stratify Patient Groups
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune cell dysregulation, chronic inflammation and increased cardiovascular risk. Disease onset dominates mid-puberty…Abstract Number: 2976 • 2017 ACR/ARHP Annual Meeting
Identification of Systemic Lupus Erythematosus Causal Risk Variant Candidates Spanning the UBE2L3 Haplotype
Background/Purpose: SLE is a prototype systemic autoimmune disease. Genome-wide association studies have fine mapped a 67kb risk haplotype that spans the Ubiquitin-conjugating enzyme E2 L3…Abstract Number: 2977 • 2017 ACR/ARHP Annual Meeting
Molecular Phenotypes Associated with Clinical Disease Activity in Adult Systemic Lupus Erythematosus
Background/Purpose : Remarkable clinical and pathophysiological diversity complicate diagnosis, treatment and therapeutic development in systemic lupus erythematosus (SLE). This study used molecular phenotyping to identify…Abstract Number: 2978 • 2017 ACR/ARHP Annual Meeting
OX40/OX40L Axis Impairs Follicular and Natural Regulatory T Cell Function in Human Systemic Lupus
Background/Purpose: Regulatory T cells (Treg) are impaired in human Systemic Lupus Erythematosus (SLE) and contribute to T cell activation. However, the mechanisms responsible for the…Abstract Number: 2979 • 2017 ACR/ARHP Annual Meeting
The Expression of Mitochondrial Molecules in Microparticle Immune Complexes in the Blood of Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by immune complexes, especially those with nuclear molecules bound by antinuclear antibodies. Although the…Abstract Number: 2980 • 2017 ACR/ARHP Annual Meeting
Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Background/Purpose : Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles of chemokines CCL19/21 and their receptor…
ACR Meeting Abstracts